Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

Detectable measurable residual disease (MRD) is the most important prognostic factor for B-cell acute lymphoblastic leukemia (B-ALL) for overall survival (OS) and disease-free survival (DFS). Patients who are MRD positive and have no access to novel immunotherapies should receive an allogeneic hematopoietic stem cell transplantation (HSCT). Blinatumomab is considered a standard of care (SOC) for this group of patients, however, the ideal treatment dose for MRD is unknown as doses were adjusted from the relapsed/refractory setting. Preliminary data suggest short cycles of blinatumomab can also

Trial Details

NCT ID

NCT06886074

Phase

PHASE2

Sponsor

Hospital Universitario Dr. Jose E. Gonzalez

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

Short course of blinatumomab

Locations (sample)

Monterrey, Nuevo León, Mexico|25.68435,-100.31721

Key Eligibility Criteria

Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia
MRD detectable in complete response (above the limit of quantification according to FCM)
Performance status 0-2 on the ECOG scale
No prior organ damage

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →